ArticleMolecular therapy. Oncology2026

ICAM1-targeted costimulation extends HER2 CAR T cytotoxicity to HER2-low and HER2-negative tumors through synergy with TCR signaling.

Yogindra Vedvyas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.